European-Society-for-Paediatric-Nephrology,Athens,Greece

European-Society-for-Paediatric-Nephrology,Athens,Greece-Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Nephrology (ESPN) 2025

Congress Details

15-18 October, 2025 | Athens, Greece

Athens, Greece

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to lumasiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Congress Materials

Presentation Type

Presentation

Location

Athens, Greece

Title

Long-Term Efficacy, Safety, and Growth Outcomes in the Phase 3 ILLUMINATE-B Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Access Prescribing Information

Presentation Type

Poster

Location

Athens, Greece

Title

Descriptive Analysis of Real-World Enrolment Data of Paediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE)

Presentation Type

Poster

Location

Athens, Greece

Title

Kidney Function, Isolated Kidney Transplant, and Health-Related Quality of Life Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-Term Lumasiran

Access Prescribing Information